Approved Hospital Formulary
Add Formweb to your mobile device
Approved Hospital Formulary
Search results for:
Adalimumab
adalimumab
- Non-formulary Miscellaneous Programs
| Drug Name | Form | Strength | Formulary Unrestricted | Formulary Restricted | Non-Formulary | Interchange |
|---|---|---|---|---|---|---|
| Abrilada | INJECTION, SUBCUTANEOUS | 10 mg/0.2 mL, 20 mg/0.4 mL, 40 mg/0.8 mL | ||||
| Amjevita | INJECTION, SUBCUTANEOUS | 20 mg/0.4 mL, 40 mg/0.8 mL | ||||
| Cyltezo | INJECTION, SUBCUTANEOUS | 40 mg/0.8 mL | ||||
| Hadlima | INJECTION, SUBCUTANEOUS | 40 mg/0.8 mL | ||||
| Hulio | INJECTION, SUBCUTANEOUS | 40 mg/0.8 mL, 20 mg/0.4 mL | ||||
| Humira | INJECTION, SUBCUTANEOUS | 40 mg/0.8 mL, 80 mg/0.8 mL | ||||
| Hyrimoz | INJECTION, SUBCUTANEOUS | 40 mg/0.8 mL | ||||
| Idacio | INJECTION, SUBCUTANEOUS | 40 mg/0.8 mL | ||||
| Simlandi | INJECTION, SUBCUTANEOUS | 40 mg/0.4 mL, 80 mg/0.8 mL | ||||
| Yuflyma | INJECTION, SUBCUTANEOUS | 40 mg/0.4 mL | ||||
| Yusimry | INJECTION, SUBCUTANEOUS | 40 mg/0.8 mL |
Last updated: Feb. 4, 2026
- Black Box Warning: Infection risk; malignancy in children and adolescents
Humira medication guide
Humira and all biosimilars were classified as therapeutically equivalent and interchangeable for the FDA approved indications and literature-supported off-label uses if need arises in adult patients.
Inpatients may use home supply.
As of May 2022, the HUMIRA First Dose Program (a no cost loading dose) has been discontinued by the manufacturer.
If the loading dose is ordered, the pharmacist should contact the prescriber and inform them that the program has been discontinued.
Dose administration should be deferred until after discharge.
Reviewed: March 25, 2014 (IBD loading dose), January 2022 (Biosimilars), April 2023 (Idacio), September 2023 (Yusimry), October 2025 (Simlandi), Dec 2025 (Yuflyma)
Update: May 2022 (First Dose Program Discontinued)
Spotlight Adalimumab-aacf (Idacio)
Adalimumab-aqvh (Yusimry)
adalimumab-ryvk (SIMLANDI) Spotlight.pdf
adalimumab-atty (YUFLYMA) .pdf